Patients must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm)\r\n* Note: The following do NOT qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) \r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement parameters noted above
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease: \r\n* Malignant fluid collections (e.g., ascites, pleural effusions)\r\n* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n* Previously radiated lesions that have not demonstrated clear progression post radiation\r\n* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG)+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease: \r\n* Malignant fluid collections (e.g., ascites, pleural effusions)\r\n* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n* Previously radiated lesions that have not demonstrated clear progression post radiation \r\n* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n** Bone lesions without an associated soft tissue mass >= 10 mm in greatest diameter; bone lesions with an associated soft tissue mass >= 10 mm in greatest diameter imaged by computed tomography (CT) or MRI are considered measurable
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease:\r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n** Previously radiated lesions that have not demonstrated clear progression post radiation\r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: the following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease:\r\n* Malignant fluid collections (e.g., ascites, pleural effusions)\r\n* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n* Previously radiated lesions that have not demonstrated clear progression post radiation\r\n* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have radiographically measurable disease (with the exception of those with neuroblastoma)\r\n* Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm)\r\n* Note: the following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by metaiodobenzylguanidine (MIBG) scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted in patients with neuroblastoma who do not have measurable disease but have MIBG-avid evaluable disease \r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurements noted above
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol specified therapy, the patients must have radiographically measurable disease; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease:\r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or CSF \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1